Addition of Gleostine to Usual Treatment for Newly Diagnosed MGMT Methylated Glioblastoma

Short Title: NRG-BN011

Enrollment Status: Active, not recruiting

NCT #: NCT05095376

Specialty Area: Oncology

Condition Studied: Glioblastoma

Age Groups: Adult; Older Adult

Phase: III

Study Information

Summary / Purpose

To find out if adding lomustine (Gleostine) to the usual treatment of temozolomide and radiation therapy helps shrink or stabilize glioblastoma in people with MGMT methylated tumors.

Study Type: Interventional

Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

Adults 18+ years of age
Newly diagnosed glioblastoma or gliosarcoma that is MGMT methylated
Eligible for radiation therapy and chemotherapy

What's Involved

Participation in the study will include:

Treatment with temozolomide given orally and radiation therapy, with or without lomustine (Gleostine) given orally
MRI scans to monitor tumor response
Questionnaires

Principal Investigator

Mauricio Perez Davila, MD

General Neurology

A Member of

(775) 982–5000

Renown Institute for Neurosciences

View Provider

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT05095376

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

Health & Wellness eNews